Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man

Reference

• BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261–270.
   PubMed Web of Science ®Google Scholar
• BROCKS, D. R. and JAMALI, F., 1991, Enantioselective pharmacokinetics of etodolac in the rat: tissue distribution, tissue binding, and in vitro metabolism. Journal of Pharmaceutical Sciences, 80, 1058–1061.
   PubMedGoogle Scholar
• BROCKS, D. R., JAMALI, F. and RUSSELL, A. S., 1991, Stereoselective disposition of etodolac enantiomers in synovila fluid. Journal of Clinical Pharmacology, 31, 741–746.
   PubMedGoogle Scholar
• BROCKS, D. R., JAMALI, F., RUSSELL, A. S. and SKEITH, K. J., 1992, The stereoselective pharmacokinetics of etodolac in young and elderly subjects, and after cholecystectomy. Journal of Clinical Pharmacology, 32, 982–989.
   PubMedGoogle Scholar
• CAYEN, M. N., KRAML, M., FERDINANDI, E. S., GRESELIN, E. and DVORNIK, D., 1981, The metabolic disposition of etodolac in rats, dogs, and man. Drug Metabolism Reviews, 12, 339–362.
   PubMed Web of Science ®Google Scholar
• CHESNE, C., GUYOMARD, C., GUILLOUZO, A., SCHMID, J., LuDWIG, E. and SAUTER, T., 1998, Metabolism of meloxicam in human liver involves cytochrome P4502C9 and 3A4. Xenobiotica, 28, 1–13.
   PubMed Web of Science ®Google Scholar
• COUNDOURIS, J. A., GRANT, M. H., ENGESET, J., PETRIE, J. C. and HAWKSWORTH, G. M., 1993, Cryopreservation of human adult hepatocytes for use in drug metabolism and toxicity studies. Xenobiotica, 23, 1399–1409.
   PubMed Web of Science ®Google Scholar
• DERMERSON, C. A., HUMBER, L. G., PHILIPP, A. H. and MARTEL, R. R., 1976, Etodolac acid and related compounds. Chemistry and anti-inflammatory actions of some potent di- and trisubstituted 1,3, 4,9-tetrahydropyrano [3,4-b]indole-1-acetic acids. Journal of Medicinal Chemistry, 19, 391–395.
   PubMedGoogle Scholar
• EBNER, T. and BURCHELL, B., 1993, Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases. Drug Metabolism and Disposition, 21, 50–55.
   PubMed Web of Science ®Google Scholar
• FERDINANDI, E. S., SEHGAL, S. N., DERMERSON, C. A., DUBUC, J., ZILBER, J., 1986, Disposition and biotransformation of 14C-etodolac in man. Xenobiotica, 16, 153–166.
   PubMed Web of Science ®Google Scholar
• FINDLAY, K. A., KAPTEIN, E., VISSER, T. J. and BURCHELL, B., 2000, Characterization of the uridine diphosphate-glucuronosyltransferase-catalyzing thyroid hormone glucuronidation in man. Journal of Clinical Endocrinology and Metabolism, 85, 2879–2883.
   PubMed Web of Science ®Google Scholar
• FISHER, M. B., CAMPANALE, K., ACKERMANN, B. L., VANDENBRANDEN, M. and WRIGHTON, S. A., 2000, In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metabolism and Disposition, 28, 560–566.
   PubMed Web of Science ®Google Scholar
• GREEN, M. D. and TEPHY, T. R., 1996, Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metabolism and Disposition, 24, 50–55.
   Google Scholar
• HAMMAN, M. A., THOMPSON, G. A. and HALL, S. D., 1997, Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochemical Pharmacology, 54, 33-41. HONDA, K., NAKAMURA, A., MORINO, A. and NOMURA. A., 1991, Studies on the metabolic fate of etodolac (IV): stereoselective disposition of etodolac in rats. Iyakuhin Kenkyu, 22, 147–151.
   Google Scholar
• JAMALI, F., 1988, Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs. European Journal of Drug Metabolism and Pharmacokinetics, 13, 1–9.
   PubMed Web of Science ®Google Scholar
• JAMALI, F., MEHVAR, R., LEMKO, C. and ERADIRI, 0., 1988, Application of a stereo-specific high-performance liquid chromatography assay to a pharmacokinetic study of etodolac enantiomers in humans. Journal of Pharmaceutical Sciences, 77, 963–966.
   Google Scholar
• JAMALI, F., MEHVAR, R. and PASUTTO, F. M., 1989, Enantioselective aspects of drug action and dispositions: therapeutic pitfalls. Journal of Pharmaceutical Sciences, 78,695–715.
   PubMed Web of Science ®Google Scholar
• Juv, C., MINERS, J., LILLYWHITE, K. and MACKENZIE, P., 1993 Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diposphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. Journal of Pharmacology and Experimental Therapeutics, 264, 475–479.
   PubMedGoogle Scholar
• KING, C., TANG, W., NGUI, J., TEPHY, T. and BRAUN, M., 2001, Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicological Sciences, 61, 49–53.
   PubMed Web of Science ®Google Scholar
• KRAML, M., HICKS, D. R., MCKEAN, M., PANAGIDES, J. and FURST, J., 1988, The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis. Clinical Pharmacology and Therapeutics, 43, 571–576.
   PubMedGoogle Scholar
• LOWRY, 0. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, A. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   Google Scholar
• NAKAJIMA, M., INOUE, T., SHIMADA, N., TOKUDOME, S., YAMAMOTO, T. and KUROIWA, Y., 1998, Cytochrome P450 2C9 catalyzes indomethacin 0-demethylation in human liver microsomes. Drug Metabolism and Disposition, 26, 261–265.
   PubMed Web of Science ®Google Scholar
• PRITCHARD, M., FOURNEL-GIGLEUX, S., SIEST, G., MAKENZIE, P. and MAGDALOU, J., 1994, A recombinant phenobarbital-inducible rat liver UDP-glucuronosyl-transferase (UDP-glucur-onosyltransferase 2B1) stably expressed in V79 cells catalyzes the glucuronidation of morphine phenols and carboxylic acid. Molecular Pharmacology, 45, 42–50.
   Google Scholar